China Pharma Univ. CDK9 compound 21a

China Pharma Univ. CDK9 compound 21a: sourced facts only. name: "Among them, compound 21a emerged as a highly selective CDK9 inhibitor (IC50 = 6.7 nM), exhibiting over 80-fold selectivity towards most other CDK family members and high kinase selectivity." [PMID:37572539]; target: "Among them, compound 21a emerged as a highly selective CDK9 inhibitor (IC50 = 6.7 nM), exhibiting over 80-fold selectivity towards most other CDK family members and high kinase selectivity." [PMID:37572539]; developer: "Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, PR China." [PMID:37572539]; stage: "Notably, 21a demonstrated significant inhibition of tumor growth in the Mv4-11 xenograft tumor model." [PMID:37572539]